Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Intravenous Paracetamol in Manament of Labour Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primiparous~* aged 18-35 years,~* Term live singleton pregnancy,~* Vertex presentation,~* Spontaneous onset of labor at term 37-42 weeks gestation,~* In active phase of of 1st stage of labour (cervix dilatation 3- 4 cm).~Exclusion Criteria:~Clinical evidence of cephalopelvic disproportion~* Use of any kind of analgesia prior to study~* Any medical disorder during pregnancy (liver or kidney impairment)~* Induction of labor, Intrauterine fetal death~* Evidence of fetal distress~* Antenatal diagnosis of congenital malformation~* Previous history of hypersensitivity to either drug~* Extremes of age (i.e. below 18 or above 35)~* Multiple pregnancies~* Cervical dilatation more than 6 cm.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- paracetamol group (Type: ACTIVE_COMPARATOR): Included 48 pregnant women who received 1000 mg of intravenous paracetamol. The treatment was administered at the begining of the active phase of 1st stage of labor \[roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%\].
- pethidine group (Type: ACTIVE_COMPARATOR): Included 48 pregnant women who received 50 mg of intravenous pethidine HCL diluted in 10 ml normal saline. The treatment was administered at the beginning of the active phase of 1st stage of labor \[roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%\].

Based on this trial design, predict the completion outcome and termination type (if applicable).